Indiana’s competitive advantage: Why compliance is an economic development strategy

By John Duffin, CEO, Pinnaql

Originally published by Inside Indiana Business on March 11, 2026

Indiana has long been known for its manufacturing strength. From automotive to orthopedics to pharmaceuticals, our state understands how to build, scale, and deliver complex products. But as life sciences enters a new era defined by advanced therapies, digital systems, and global regulatory scrutiny, a new competitive advantage is emerging. It is not just innovation. It is compliance.

Compliance is often viewed as a cost of doing business. In reality, it is economic infrastructure.

For companies operating in regulated industries such as pharmaceuticals, medical devices, and biotechnology, regulatory readiness determines whether a product launches on time or sits idle. It influences whether capital flows into a region or moves elsewhere. It shapes whether an acquisition succeeds or stalls under scrutiny.

Indiana is uniquely positioned to lead in this space.

Consider the rapid growth of cell and gene therapies. These treatments are personalized, data intensive, and operationally complex. This compounds the requirements in comparison to traditional mass manufacturing, they require strict chain of custody controls, digital traceability, validated systems, and disciplined quality governance at every step. A single gap in documentation or data integrity can delay approval and disrupt patient access.

Companies that embed compliance into their operating model from the outset move faster and attract greater investment confidence.

We have seen this play out across the Midwest. One Indiana manufacturer recently accelerated a new production line for a strategic therapy by compressing its timeline from 15 months to nine. The difference was not just engineering speed. It was disciplined project governance, integrated validation planning, and early alignment between operations and quality teams to ensure inspection readiness. By aligning compliance with execution, the organization preserved millions in projected launch revenue.

This is not just a life sciences story. It is a business lesson.

Private equity firms and strategic investors increasingly evaluate operational maturity before committing capital. They assess quality systems, audit history, data governance, and leadership depth. Regions that cultivate a strong workforce of validation engineers, quality professionals, and regulatory strategists become more attractive because risk is lower and scalability is higher.

Indiana’s life sciences cluster includes global pharmaceutical manufacturers, emerging biotech firms, CDMOs, and medical device innovators. What strengthens this ecosystem is not only scientific talent but also a culture of precision and accountability rooted in our manufacturing heritage.

The rise of digital manufacturing reinforces this advantage.

As facilities adopt automation, connected equipment, and AI-enabled quality systems, compliance becomes even more central. Systems must meet 21 CFR Part 11 requirements (governing electronic records and signatures). Data must be attributable, legible, contemporaneous, original, and accurate (ALCOA++). Cybersecurity now intersects directly with product integrity. Operational technology teams now collaborate closely with quality and regulatory leaders.

Organizations that treat digital transformation and compliance as separate tracks create friction. Those that integrate them create momentum.

Indiana companies are increasingly recognizing that audit readiness is not a last-minute activity before an FDA visit. It is a daily operating discipline. In one recent initiative, a manufacturer standardized data integrity practices across hundreds of laboratory and manufacturing systems. By implementing consistent access controls, audit trail reviews, and governance frameworks, the company reduced regulatory exposure while improving operational visibility. Leaders could make faster decisions because they trusted their data.

That trust translates directly into economic value.

For the broader business community, the lesson is clear. Compliance excellence builds reputational capital. It strengthens supplier relationships. It enhances workforce pride. It signals to global partners that Indiana companies operate at world-class standards.

As advanced therapies expand and manufacturing becomes more personalized, our state has an opportunity to lean into what it already does well. We understand engineering. We understand process discipline. We understand collaboration between industry, academia, and government.

To sustain this momentum, workforce development must evolve alongside technology. Universities and technical programs should continue investing in validation science, automation engineering, quality systems, and data governance. Business leaders should view compliance talent not as overhead but as strategic infrastructure.

Indiana’s future in life sciences will not be defined solely by scientific discovery. It will be defined by our ability to operationalize innovation safely, efficiently, and at scale.

When compliance is embedded into strategy, growth becomes more predictable. Investment becomes more confident. Innovation reaches patients faster.

In a competitive global market, that is not simply regulatory discipline. It is economic advantage.

With offices in both Indiana and Pennsylvania, Pinnaql is a consulting partner to regulated life sciences companies—bringing deep technical, validation, and quality expertise to every stage of the product lifecycle. We help pharma, biotech, and medical device companies overcome complexity, accelerate timelines, and stay audit-ready.